Loading the records…
Loading the records…
HR8462 is a procedural reauthorization bill for the National Quantum Initiative Act that was marked up and reported out of committee on April 29, 2026. The bill text as provided authorizes zero specific funding amounts — it only updates statutory definitions and cross-references to other laws. Pure-play quantum stocks (IONQ, RGTI, QBTS) have rallied 19-57% over the past 30 days but pulled back 9-15% in the past week, reflecting sector profit-taking rather than a market reaction to this specific bill introduction.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The market has already priced in continued quantum sector momentum independent of HR8462. IONQ at $44.03, RGTI at $16.72, and QBTS at $19.54 all sit well above their respective 52-week lows ($25.89, $8.94, $6.82) but below their highs ($84.64, $58.15, $46.75). The sector's 19-57% monthly gain with a 9-15% pullback over the past week suggests rotational profit-taking rather than a fundamental catalyst shift. IBM at $229.41 is near its 52-week low of $220.72, making it the value play in the space if one believes quantum computing will eventually benefit Big Blue — but HR8462 is not the catalyst for that thesis. Traders should not confuse this bill's procedural progress with a fundamental revenue catalyst. The causal chain between a definition-amending bill and company earnings is broken — no contract, no grant, no tax credit is created here. The real quantum market catalyst to watch is either: (a) a separate appropriations bill that allocates specific quantum funding, or (b) an agency procurement action (e.g., DOE's quantum computing program for national labs). HR8462 is background noise for valuation.
HR8462, the National Quantum Initiative Reauthorization Act, was introduced on April 23, 2026 by Rep. Randy Weber (R-TX-14) with two cosponsors. The bill was referred to the House Committee on Science, Space, and Technology, marked up on April 29, and ordered to be reported (amended) by voice vote — meaning it has cleared committee but awaits floor action in the House. This is an early-stage procedural bill in the 119th Congress (2025–2027).
The money trail is critical here: this bill authorizes no specific dollar amounts. The National Quantum Initiative Act (originally passed in 2018) is a coordination framework for quantum R&D across DOE, NSF, and NIST — but actual funding requires separate appropriations bills. The bill text provided shows HR8462 only amends definitions, including adding references to 'foreign entity of concern' from the CHIPS and Science Act, and clarifying terms like 'quantum applications.' Without a funding level, the economic impact on quantum companies is effectively zero from this specific legislative action.
Structural winners (in the context of the broader NQI Act, not this specific bill) remain the pure-play quantum computing companies: IonQ (IONQ), Rigetti Computing (RGTI), and D-Wave Systems (QBTS), as well as larger diversified tech firms with quantum divisions like IBM (IBM), Alphabet (GOOGL), and Microsoft (MSFT). However, none of these companies receive a direct revenue boost from HR8462 as introduced. IBM's quantum business, while strategically important, remains a negligible portion of its $60B+ revenue base.
Market data from the past 30 days shows significant appreciation across quantum stocks: IONQ +52.72%, QBTS +35.34%, and RGTI +19.09%. However, over the past week these same names have cooled: IONQ -3.14% (based on the 7-day change to $44.03 from the prior week's close near $46), though the bill's April 23 introduction doesn't correspond to any clear trading anomaly in the closing prices. IBM, a diversified bellwether, is down -5.36% over 30 days to $229.41 — its decline correlates with broader tech weakness, not quantum-specific news.
The legislative path forward: the bill must pass the full House, then the Senate, and be signed by the President. Even then, it merely reauthorizes a policy framework — any actual funding for quantum programs requires separate appropriations bills that have not yet been introduced. This is a low-velocity, early-stage procedural action that signals continued congressional interest in quantum but creates no near-term catalyst for quantum stock revenue.
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend the National Quantum Initiative Act to make certain additions relating to quantum modeling and simulation, and for other purposes.
A bill to amend the Export-Import Bank Act of 1945 to include quantum information science and technology in the areas covered by the Program on China and Transformational Exports.
A bill to require the Secretary of Defense to support development of quantum technologies, and for other purposes.
National Quantum Initiative Reauthorization Act of 2026
Executive orders & memoranda affecting the same sectors or companies
The President invokes Section 232 of the Trade Expansion Act to declare that imports of robotics, industrial machinery, and their components threaten national security, and directs the Secretary of Commerce and USTR to negotiate agreements with trading partners to adjust these imports, potentially leading to tariffs or quotas within 180 days.
This proclamation initiates negotiations to adjust imports of wind turbines and their components under Section 232, citing national security concerns including cybersecurity vulnerabilities, radar interference, and grid reliability. It does not immediately impose tariffs but sets the stage for potential trade restrictions, and notes that certain wind turbine components made of aluminum, steel, or copper are already subject to existing tariffs.
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →